Finance entity
Every one of those 1 sits in a single category, markets. Casgevy is most often covered alongside CRISPR Therapeutics, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Casgevy appears in 1 tracked Finance story from September 3, 2026.
Last mentioned: 18h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Casgevy is most often covered alongside CRISPR Therapeutics, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Casgevy appears in 1 tracked Finance story from September 3, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Casgevy. Shared-story counts are live from our verified record — not editorial picks.
CRISPR Therapeutics has lagged the broader market in 2026, but Casgevy's label expansion and upcoming clinical readouts create two discrete catalysts that could re-rate the stock. Downside risk remains from slow uptake and high cost.
Casgevy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
